Several studies have shown that up to 25% of breast cancers overexpress a member of the HER/ErbB transmembrane receptor tyrosine kinase family, ErbB2, associated with poor prognosis and with a more aggressive clinical behaviour (Baselga and Albanell, 2001). This evidence concerns the gene ERBB2 and breast cancer.